• Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP
ERA-EDTA
  • ABOUT ERA-EDTA
      • WHO WE ARE
      • History
      • ERA-EDTA Facts and Dates
      • Pioneers of the European Nephrology
        • Interviews with the Masters of Nephrology
      • Obituaries
      • Mission
      • ORGANIZATION & GOVERNANCE
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
        • Candidatures Boards and Calls
      • ORGANIZATION & GOVERNANCE
      • Group & Staff
        • ERA-EDTA
          • ERA-EDTA Operative Headquarters
        • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Disclosure of Interest (DoI)
      • Annual Reports
      • Accounts
      • ERA-EDTA Membership
      • Benefits
      • Fees
      • Renewal
      • Members: Senior – Junior
      • Honorary Members
      • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Past Congresses
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Patient Information
      • Initiatives for patients
      • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
      • NDT
      • CKJ
      • Cardio-renal research
      • EDTA Proceedings
      • Newsletter & Press Releases
        • Nephrology News Flash
        • NEP Newsletter
        • Press Releases
      • News
      • EDTA Proceedings
      • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
      • National Societies of Nephrology List
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • Biomedical Alliance in Europe
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Search
  • Menu
  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
  • MEMBERSHIP
  • My Era-Edta
  • Contact us
  • ABOUT ERA-EDTA
    • Who we are
      • History
      • ERA-EDTA Facts and Dates
      • Mission
    • Organization & Governance
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
    • Group & Staff
      • ERA-EDTA
      • ERA-EDTA Operative Headquarters
      • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Annual Reports
      • Accounts
    • ERA-EDTA Membership
      • Benefits
      • Membership Fees
      • Renewal
      • Members: Senior – Junior
    • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Initiatives for patients
    • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
    • NDT
    • CKJ
    • Cardio Renal Research
    • Newsletter & Press Releases
      • Nephrology News Flash
      • NEP-Nephrology Education Portal Newsletters
      • Press Releases
    • News
    • EDTA PROCEEDINGS
    • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP

Long Term Fellowships

WHAT THEY ARE

The purpose of the ERA-EDTA Young Long-Term Fellowships is to support basic and clinical research in the field of Nephrology in the ERA-EDTA geographical area (Europe, countries bordering Europe and the Mediterranean Sea), in particular to favor the growth of the young investigators living in Europe.

Starting from 2019, to enhance integration of the ERA-EDTA activities, the ERA-EDTA Long Term Fellowships are assigned to competitive research proposals by the ERA-EDTA Committees, with the aim to simultaneously finance the worthy ERA-EDTA Committee’s projects and to favor young researchers’ growth.

WHERE THEY ARE PERFORMED

The Long Term Fellowships are performed in receiving institutions located in the ERA-EDTA geographical area (Europe, countries bordering Europe and the Mediterranean Sea).

The young investigators submitting their candidature for an ERA-EDTA Long Term Fellowship will be asked to identify the project they would like to join and thus apply for it. Each scientific project will be carried out in a specific  Centre located within the ERA-EDTA geographical area.

WHAT IT IS OFFERED

The duration of the Long Term Fellowships is  12 months (365 days).

The fellowship subsistence rates are based on the calculations done on the basis of the EMBO -European Molecular Biology Organization-rates: the flat fee figures (available here) are for a period of 12 months and should cover travel and living expense and any work -related taxes and insurances. For a shorter/longer period the amount must be calculated accordingly

WHO CAN APPLY

Applications are only considered from Full ERA-EDTA Members whose age will not be over 40 at the time of the application submission.

Criteria used for the selection.

1. Age of the applicant

2. Prior expertise of the applicant

3. How the project the applicant fits into his/her career

4. Feasibility of the project by the applicant.

Moreover, specific qualifications and expertise requirements are specifically outlined in each scientific project.

HOW TO APPLY

The Call will be opened on March 5, 2020 and will close on April 30, 2020 (deadline for applications).

In order to submit your Fellowship request you must fill in a specific application form (accessible to ERA-EDTA members only).

The young investigators submitting their candidature for an ERA-EDTA Long Term Fellowship will be asked to identify the project they would like to join (read more about the 4 available projects at bottom of this page) and thus apply for it. Each scientific project will be carried out in a specific Centre located within the ERA-EDTA geographical area.

FOR FURTHER QUERIES

For the complete instructions and rules please read the Long Term Fellowship Regulations

For all questions about ERA-EDTA Young Fellowship Programme, please contact the ERA-EDTA Operative Headquarters at fellowships@era-edta.org.

Click on the tabs below to learn more about the available scientific projects
Prognosis and outcome in patients with primary membranous nephropathy

In collaboration with DESCARTES Working Group

Prognosis and outcome in patients with primary membranous nephropathy

PROJECT DESCRIPTION

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome. The natural history is variable, approximately 50% of patients developing remission, whereas 50% of patients develop ESRD. Although alkylating agents reduce ESRD risk by 80%, their use is associated with high toxicity. Alternative therapies are used, such as rituximab and tacrolimus, but have not been tested against cyclophosphamide. There is a unmet need to develop strategies based on prognostic and predictive biomarkers to allow optimized, individualized therapy for MN. Serum creatinine and proteinuria are not very accurate. Thus, we need more information on useful prognostic and predictive biomarkers, and also need comparative studies between currently use treatment modalities (and potential new agents such as bortezomib).

In 2009 measurement of antibodies against PLA2R was introduced, and initial data suggested that quantitative analysis might provide information on prognosis and treatment response. In rare diseases, comparative effectiveness studies using prospectively collected data could allow meaningful conclusions about safety and effectiveness. In 2012 Centers from Paris, Manchester, Nijmegen, and Prague started a registry which contains data of > 400 patients with MN. The goal is enlarge this registry, in collaboration with adult expert centers who participate in ERKnet.

The goals of the project are:

  1. To enlarge the registry and add PLA2Rab data, using stored biobank samples when available, and obtain detailed information on treatment and outcome.
  2. To identify clinical and laboratory characteristics that allow to predict outcome.
  3. To compare different treatment regimens using adjusted analyses/propensity scoring.
  4. To evaluate treatment response to off-label used therapies such as Bortezomib and daratumumab.
  5. Extension of the registry to include patients with MN after kidney transplantation, and evaluate risk of recurrence, predictive factors, and outcome with therapy

The research fellow will be responsible for the coordination between centers, to optimize the database, aid in retrieving the relevant biomarker data, analyse the data and write a final report.

DETAILS OF THE FELLOWSHIP 

  1. Duration of the fellowship: 12 months
  2. Location of the hosting centre: Department of Nephrology, 464 Geert Grooteplein Zuid 86525 GA Nijmegen, The Netherlands; Phone: +31243614761 Contact person for administrative issues: Mrs Linda Kusters Linda.kusters@radboudumc.nl or Mrs Mary Hakvoort Mary.hakvoort@radboudumc.nl
  3. Principal Investigator and Supervisor of the project: Jack .F.M. Wetzels, Prof.
  4. Start of the fellowship: January 2021
  5. Qualifications and/or expertise required:  the applicant must be fluent in spoken and written English, study in medicine or biomedical sciences, have experience with statistical data analysis, proven expertise in research in the field of nephrology, auto-immune diseases is preferred, being a team-player, with societal skills.

GRANTED AMOUNT

EUR 39,000

DOWNLOAD

Renal disease in obesity-overweight-metabolic syndrome and diabetes

In collaboration with the Immunonephrology Working Group

Renal disease in obesity-overweight-metabolic syndrome and diabetes

PROJECT DESCRIPTION

The epidemic of obesity and type 2 diabetes (T2DM) may portend severe consequences in nephrology. Obesity and diabetes represent a continuum of metabolic alterations which can greatly increase the chance of renal disease. Common markers of renal damage in diabetes and obesity include i.e. insulin resistance, hypertension, prediabetic alterations in glucose metabolism, insulin resistance, hyperuricaemia, dyslipidemia and lipotoxicity, chronic sub-clinical inflammation, unhealthy obesity, glomerular hyperfiltration and albuminuria. Renal histological changes associated with obesity (metabolically healthy or unhealthy) and early diabetic nephropathy are mostly unknown. The major limitation for studying early histological changes of obesity and diabetes is that renal biopsies are not performed due to ethical concerns. To solve this limitation, we propose the creation of a bio-bank of unaffected renal tissue of pieces of nephrectomy, to study the following points: (a) the histological pattern of renal damage in the whole spectrum of obesity (not only extreme obesity); (b) histological changes in healthy and unhealthy obesity with the same degree of BMI; (c) similarities in renal histology between early diabetes and metabolically unhealthy obesity; (d) the impact of metabolic factors on obesity-related renal damage; (e) possible pathogenetic pathways i.e. lipotoxicity or sub-clinical inflammation in obesity driven renal disease; (f) the prevalence of markers of chronic disease i.e. glomerulsclerosis, tubular and interstitial fibrosis in patients with obesity and early diabetes. This also will give the possibility of analyzing pathogenetic pathways involved in renal damage associated with these diseases.

DETAILS OF THE FELLOWSHIP 

  1. Duration of the fellowship: 12 months
  2. Location of the hosting centre: University of La Laguna -La Laguna, Tenerife Spain, Faculty of Medicine, Campus de Ofra, s/n, 38071 San Cristóbal de La Laguna, Santa Cruz de Tenerife (Spain)
  3. Principal Investigator Esteban Porrini, MD Supervisor of the project Rosa Rodriguez, MD
  4. Start of the fellowship: January 2021
  5. Qualifications and/or expertise required: Biologist with experience in renal pathology, morphometric evaluations, histological evaluation, different stainings i.e. inflammation, fibrosis, etc  and lipidomic analysis.

 GRANTED AMOUNT

EUR 32,000

DOWNLOAD

 

Does kidney transplantation improve survival in the current era in Europe? Analysis of several European registries

In collaboration with the ERA-EDTA Registry

Does kidney transplantation improve survival in the current era in Europe? Analysis of several European registries

PROJECT DESCRIPTION

Older studies have shown a survival benefit with kidney transplantation compared to dialysis, even for patients older than 60 years. However, due to important evolutions such as older recipient age and the use of less-than-optimal quality donors, as well as improved survival on dialysis, it is unclear if the survival benefit with transplantation still holds true nowadays.  Recently, we performed a pilot study in a Belgian cohort of patients waitlisted for a first deceased donor kidney transplant between 2000 and 2012. We analyzed survival of those who were transplanted, either with a standard criteria donor (SCD) kidney or expanded criteria donor (ECD) kidney, and compared this to the survival of those who remained on dialysis. Our analysis suggests that recipients ≥ 65 years have a survival benefit when transplanted with an SCD, but that their survival benefit with an ECD may be small or non-existent. However, the relatively low number of patients leads to estimates with considerable uncertainty. These preliminary findings should be re-evaluated and studied in more depth in a larger European cohort.

Therefore, in the current research project, we aim to expand the analysis to include data from other European countries. A large international European database would not only lead to more precise estimates of survival with transplantation versus dialysis, but it could also enable a better assessment of the prognostic value of individual donor and recipients characteristics on outcomes.

This fellowship could lead to a long-term collaboration with the ERA-EDTA registry, the Descartes working group members, and the responsible persons of several European renal registries.

DETAILS OF THE FELLOWSHIP 

  1. Duration of the fellowship: 12 months
  2. Location of the hosting centre: The primary hosting center is the ERA-EDTA Registry in Amsterdam (Netherlands), but regular visits to Antwerp (Belgium) will be required.
    ERA-EDTA Registry Department of Medical Informatics
    Amsterdam University Medical Centers
    AMC Meibergdreef 15 Room J1B-125
    1105 AZ  Amsterdam – Netherlands
    Phone: +31 20 5667637
    Contact person for administrative issues: Dr. Vianda Stel  v.s.stel@amsterdamumc.nl
    Universitair Ziekenhuis Antwerpen
    Department of Nephrology
    Wilrijkstraat 10B-
    2650 Edegem
    Belgium
    Phone: +32 3 8213435
    Contact person for administrative issues: Dr. Rachel Hellemans Rachel.Hellemans@uza.be
  3. Principal Investigator of the project:Dr. Vianda Stel and Dr. Rachel HellemansSupervisors: Dr. Vianda Stel, Dr. Rachel Hellemans, Dr. Anneke Kramer, Prof. Daniel Abramowicz and Prof. Kitty Jager.
  4. Start of the fellowship: January 2021
  5. Qualifications and/or expertise required: The fellow must have a special interest and basic knowledge of epidemiology and statistics. He/she should have substantial experience in data analysis. (Data analysis will be performed with the SAS program. Basic knowledge of programming in SAS  is a plus but not a must)

GRANTED AMOUNT

EUR 40,000

DOWNLOAD

How to set the stage for a full-fledged clinical trial testing “incremental haemodialysis”

How to set the stage for a full-fledged clinical trial testing “incremental haemodialysis”

PROJECT DESCRIPTION

The optimal regimen for patients starting haemodialysis (HD) is not known. It is plausible that the routine practice of a thrice-weekly HD (3HD/wk) regimen in incident patients with substantial residual kidney function (RKF) may be harmful, contributing to accelerated loss of RKF. At the present time no randomized controlled trial (RCT) testing “incremental HD” has yet been published [1].

The EUDIAL Working Group is starting an RCT in incident HD patients, whose name is “REAL LIFE”, by using the acronym of its whole definition: RandomizEd clinicAL triaL on the effIcacy and saFety of incremental haEmodialysis.

REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). Incident patients will be randomized to one of the two treatment groups in equal proportion. To ensure adequate concealment of allocation, the randomization will be performed using a central computer.

Patients will be recruited from dialysis centres in Europe. Primary outcome is preservation of RKF assessed as time to anuria (urine output ≤ 100 mL/day). Secondary outcomes are the slope of KRU decline over time, all-cause mortality, significant events, including vascular access failure and associated interventions, cardiovascular events, and hospital admissions. The follow-up time will be 24 months. The statistical analysis will be done by means of the intention-to-treat approach. The prescription of incremental HD will be based on the variable target model (VTM) [2]. VTM allows to start and keep patients on once-weekly HD schedule if residual renal urea clearance (KRU) is between 3.0 and 4.5 mL/min/35 L. Once-weekly HD should be possible until KRU falls below 2.5 – 3.0 mL/min/35 L, i.e., a glomerular filtration rate (GFR) ≈ 4 mL/min/35 L. All patients allocated to the intervention arm will keep on the twice-weekly schedule until KRU falls below 1.5 mL/min/35 L; afterwards, the 3HD/wk schedule must be started. The intervention arm patients (once- and twice-weekly HD schedule) should receive an equilibrated Kt/V (eKt/V) of about 1.2 per session.

The assessment of the key kinetic parameters will be done by using SPEEDY [21], a spreadsheet prescription tool. Click here to learn.

1. Basile C, Casino FG on behalf of the EUDIAL Working Group of ERA- EDTA (2019) Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrol Dial Transplant 34: 1806 – 1811

2. Casino FG, Basile C (2017) The variable target model: a paradigm shift in the incremental haemodialysis prescription. Nephrol Dial Transplant 32: 182 – 190

3. Casino FG, Basile C (2018) A user-friendly tool for incremental haemodialysis prescription. Nephrol Dial Transplant 33: 1046 – 1053

DETAILS OF THE FELLOWSHIP 

  1. Duration of the fellowship: 12 months
  2. Location of the hosting centre: Nephrology, Dialysis and Transplantation Unit “Aldo Moro” University of Bari, Azienda Ospedaliero-Universitaria Consorziale “Policlinico” Piazza Giulio Cesare, 11 – 70124 Bari, Italy; Phone +39 080 547 8622;  +39 080 559 2774 –  Fax +39 080 5478 675; Contact Person for administrative issue: Mrs Delfina Maria Miruraca  delfinamaria.misuraca@uniba.it
  3. Principal Investigators of the project: Carlo Basile, MD, Francesco G. Casino, MD Name of the Fellow’s Supervisor Loreto Gesualdo, Prof.
  4. Start of the fellowship: January 2021
  5. Qualifications and/or expertise required: expertise in biostatistics and epidemiology; previous experiences in the conduction and monitoring of randomized controlled trials.

 GRANTED AMOUNT

EUR 35,000

DOWNLOAD

LINKS AND ATTACHMENTS

  • Long Term Fellowship Regulations
  • Application Form
  • Contact us

  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on Linkedin
  • Share on Reddit
  • Share by Mail
  • Share on WhatsApp
  • Long Term Fellowships
  • Registry Fellowships
  • Short Term Clinical Fellowships
  • Special Fellowships for Greek Nephrologists (Long Term Fellowships / Short Term Research Fellowships, Short Term Clinical Fellowships)
  • Research Programme

ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org

ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom

You are here: Home / Science / Long Term Fellowships

  • ABOUT ERA-EDTA
  • CONGRESS & MEETINGS
  • JOURNAL & PRESS
  • EDUCATION
  • PUBLIC AFFAIRS
  • GUIDELINES

  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
.av-share-box ul li{ display: none!important; }

  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on Linkedin
  • Share on Reddit
  • Share by Mail
  • Share on WhatsApp
© Copyright - Era-Edta
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more